LifeVantage Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LFVN research report →
Range $6 – $8
Price Chart
About the company
LifeVantage Corporation (LFVN) specializes in the development, manufacture, and distribution of a diverse portfolio of health, wellness, and personal care products. Its offerings encompass nutrigenomic activators (designed to influence genetic expression), a broad array of dietary supplements, cognitive enhancers (nootropics), gut health support (pre- and pro-biotics), weight management solutions, and various personal care items spanning skin care, hair care, bath and body, and targeted relief. The company's product lineup features well-known brands such as Protandim, a series of scientifically validated dietary supplements.
- CEO
- Terrence Moorehead
- IPO
- 1994
- Employees
- 216
- HQ
- Lehi, UT, US
Get TickerSpark's AI analysis on LFVN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $52.63M
- P/E
- 22.31
- Fwd P/E
- 15.96
- PEG
- -0.30
- P/S
- 0.35
- P/B
- 1.79
- EV/EBITDA
- 8.62
- Div Yield
- 3.97%
- Gross Margin
- 76.54%
- Op Margin
- 2.15%
- Net Margin
- 1.58%
- ROE
- 8.17%
- ROIC
- 6.42%
Latest fiscal year · YoY change
- Revenue
- $182.59M-20.1%
- Gross Profit
- $141.61M-22.9%
- Op Income
- $6.10M
- Net Income
- $5.07M-48.3%
- EPS
- $0.40-50.0%
- OCF Growth
- -13.8%
- FCF Growth
- -36.5%
- 52W High
- $11.71
- 52W Low
- $3.90
- 50D MA
- $5.80
- 200D MA
- $5.84
- Beta
- 0.73
- RSI (14)
- 38
- Avg Volume
- 45.21K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
LifeVantage reported a sharp first-quarter revenue decline and lower profitability, but management stressed a major brand, digital, and operating-model reset backed by a strong balance sheet and no debt.· November 9, 2026
- Revenue fell 22% year over year to $37.1 million, with weaker orders and lower average order size driving the decline.
- Gross margin was 75.4%, down from 79.5%, while adjusted EBITDA was $1.9 million or 5.2% of revenue.
- Management said it is not giving formal guidance as it resets the business and changes its fiscal year to the calendar year starting January 1, 2027.
- The company ended the quarter with $13.7 million in cash, no debt, and positive operating cash flow of $500 thousand.
- Leadership laid out a broad transformation plan centered on a new brand position, a revamped digital platform, and a more efficient cost structure.
Net revenue was $37.1 million, down 22% from $47.6 million a year ago. Gross profit percentage was 75.4% versus 79.5% in the prior-year period; adjusted gross profit percentage excluding the MindBody inventory allowance was 78.2%. GAAP net loss was $200 thousand, or $0.02 per diluted share, versus net income of $2.2 million, or $0.17 per diluted share last year; adjusted non-GAAP net income was $600 thousand, or $0.05 per diluted share, versus $2.3 million, or $0.18 per diluted share. Adjusted EBITDA was $1.9 million, or 5.2% of revenue, versus $3.9 million, or 8.2% a year ago. The company ended with $13.7 million in cash and no debt, generated $500 thousand of cash from operations, and had $58.5 million remaining under its $60 million share repurchase authorization. Management did not issue formal guidance for next quarter or full year, citing the CEO transition and fiscal-year change.
Terrence O. Moorehead said he believes LifeVantage has far greater potential than its current scale, but the company needs meaningful change after a quarter marked by lower orders and lower basket size. He framed the strategy around three priorities: rebranding as a next-generation nutraceutical company, modernizing the consumer and seller experience through digital tools, and becoming more selective about where the company competes and invests. His tone was candid and reform-focused, emphasizing that the company is building a more disciplined, brand-driven, consumer-focused model rather than trying to preserve the status quo.
Carl Aure said revenue pressure was driven by fewer orders from the active consumer base, lower average order size, macroeconomic softness, and lower sales from MindBody GLP-1 System, partially offset by LoveBiome. He noted foreign currency reduced revenue by $400 thousand, subscription revenue remained more than 75% of total revenue, and retention improved versus last year. On profitability, gross margin was 75.4% and adjusted gross margin was 78.2% excluding the MindBody inventory allowance; commissions and incentives were 41.4% of revenue and management expects that line to settle around 41% to 42%, while CapEx was $1.2 million and should run around $1 million per quarter for the next couple of quarters before annualized spend trends to $3 million to $3.5 million.
Analysts focused on how the new marketing push will reach consumers, what the planned seller business suite will include, how cost savings will be redeployed, and whether commissions could move lower again. Management said the initial campaign will start with the distributor base and an email program targeting more than a half million names, then expand digitally in the new year; the seller suite is intended as a toolkit with CRM, email and text outreach, social-media tools, training, recognition, and eventually AI support and coaching. On cash flow and commissions, Carl said current free cash flow should be more predictable going forward and that commissions should remain around 41% to 42%, with only modest variability.
The company still has cash, no debt, positive operating cash flow, and a subscription base that provides more than 75% of revenue, which gives management room to execute the turnaround. Leadership also believes the brand has a differentiated science-based proposition and is starting a new campaign, digital platform, and seller toolkit that could improve engagement, retention, and growth if executed well.
The quarter showed a steep 22% revenue decline, lower gross margin, and much weaker earnings, underscoring that the business is under pressure now. Management offered no formal guidance and acknowledged that the transformation will take time, while also flagging continued investment needs in technology and a need to reset the economics and cost structure of the company.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.3%
- Shares Outstanding
- 12.68M
- Float Shares
- 10.30M
of shares held by institutions
95 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Capital Management Corp /Va | 2.31M | ▲ 429.08K |
| Renaissance Technologies LLC | 630.22K | ▼ 39.20K |
| Vanguard Group Inc | 563.28K | ▲ 2.18K |
| Vanguard Capital Management LLC | 445.33K | ▲ 16.13K |
| American Century Companies Inc | 257.23K | ▲ 112.84K |
| Blackrock, Inc. | 255.90K | ▼ 12.71K |
| Dimensional Fund Advisors LP | 239.37K | ▼ 16.93K |
| Envestnet Asset Management Inc | 229.91K | ▲ 10.74K |
| Susquehanna International Group, Llp | 169.05K | ▲ 169.05K |
| Geode Capital Management, LLC | 123.13K | ▲ 2.30K |
| Aqr Capital Management LLC | 113.20K | ▼ 42.89K |
| Goldman Sachs Group Inc | 110.86K | ▼ 74.25K |
Held by 52 ETFs
Biggest fund positions in LFVN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | BEINDORFF MICHAEL A | sell | 10,000 |
| Nov 5, 26 | BEINDORFF MICHAEL A | other | 17,888 |
| Nov 5, 26 | Anbalagan Rajendran | other | 17,888 |
| Nov 5, 26 | Lewis Darwin | other | 17,888 |
| Nov 5, 26 | Greer Raymond B | other | 17,888 |
| Nov 5, 26 | Dayton Judd | other | 17,888 |
| Oct 7, 26 | Cunningham Kristen | other | 32,850 |
| Oct 7, 26 | Cunningham Kristen | other | 49,275 |
| Oct 7, 26 | Aure Carl | other | 35,749 |
| Oct 7, 26 | Aure Carl | other | 53,623 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LFVN coverage
Recent articles, reports, and earnings notes.
No research on LFVN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LFVN report →LifeVantage Corporation (LFVN) Q1 2027 Earnings Call Transcript
seekingalpha.com · Nov 10
Lifevantage (LFVN) Surpasses Q1 Earnings Estimates
zacks.com · Nov 9
What Lifevantage (LFVN) Said on Its Q1 Earnings Call
marketbeat.com · Nov 9
LifeVantage Declares Quarterly Dividend
globenewswire.com · Nov 9
LifeVantage Announces Financial Results for the First Quarter Fiscal 2027
globenewswire.com · Nov 9
New LifeVantage Research Explores How Protandim® Nrf2 Supports Cellular Defense Against Five Modern Environmental Toxins*
globenewswire.com · Oct 29
Lifevantage (NASDAQ:LFVN) Stock Breaks Above 200 Day Moving Average – What’s Next?
defenseworld.net · Oct 28
LifeVantage to Announce First Quarter Fiscal Year 2027 Results on November 9, 2026
globenewswire.com · Oct 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.